Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for comparisons against own past, real and recurring, early stage. Scan transcript for statements about deal sizes, lease sizes, etc. Doug Linde mentions leasing activity: "We completed 1.2 million square feet of leasing more than double the space we leased in the first quarter of 2021" - that's volume, not unit size. He also says "During the month of April, so the last 30 days, we've signed in excess of 1.1 million square feet of space." That's volume. Look for specific deals: AstraZeneca lease for 570,000 square feet at 290 Binney Street. Is that presented as part of an upward drift? Owen says "AstraZeneca announced last week, they have signed a lease for 570,000 square feet to consolidate into a major research facility at BXP's 290 Binney Street development." That's a large lease, but is it compared to past? Not really. Check for any statement about average deal size increasing. Doug mentions "We completed 7 deals for 47,000 square feet" in Boston CBD, average ~6,700 sq ft. Not large. Look for "larger" or "bigger" or "longer" terms. Owen says "we completed 1.2 million square feet of leasing more than double the space we leased in the first quarter of 2021" - that's total volume, not per deal. Search for "average" or "size" or "scale". Not present. Management talks about leasing momentum, but not about individual deal sizes escalating. They mention a 330,000 sq ft extension at 601 Lexington, a 125,000 sq ft renewal at GM, a 140,000 sq ft lease at 180 CityPoint, etc. But no comparison to past deal sizes. Also, they mention "We have had 3 consecutive strong quarters of office leasing" - that's volume. No explicit statement that new deals are individually larger than before. The AstraZeneca deal is large but not framed as part of an upward drift. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.